Scarica l'app Stockscreener
81.78
3.05%
-2.57
Dopo l'orario di chiusura:
81.11
-0.67
-0.82%
Precedente Chiudi:
$84.35
Aprire:
$84.2
Volume 24 ore:
1.70M
Relative Volume:
0.71
Capitalizzazione di mercato:
$13.25B
Reddito:
$705.14M
Utile/perdita netta:
$-453.90M
Rapporto P/E:
-26.90
EPS:
-3.04
Flusso di cassa netto:
$-551.29M
1 W Prestazione:
-2.04%
1M Prestazione:
+0.15%
6M Prestazione:
+97.49%
1 anno Prestazione:
+165.18%
Intervallo 1D:
$81.20
$84.91
Intervallo di 1 settimana:
$81.20
$86.59
Portata 52W:
$23.95
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
81.78 | 13.66B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Severe Hypertriglyceridemia Market: High-Growth Opportunities for Investors to 2034DelveInsight - openPR.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance
Ionis to hold fourth quarter and full year 2025 financial results webcast - Caledonian Record
Ionis Pharma CEO Monia sells $2.52m in shares By Investing.com - Investing.com Canada
Ionis Pharma CEO Monia sells $2.52m in shares - Investing.com
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia Sells 29,430 Shares - MarketBeat
Ionis Pharmaceuticals (IONS) Valuation Check As Dawnzera Approval And Other Milestones Support Growth Prospects - Sahm
Candriam S.C.A. Has $39.99 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Stock Recap: Why is Ionis Pharmaceuticals Inc stock going upWeekly Market Report & Consistent Income Trade Ideas - baoquankhu1.vn
Wealth Enhancement Advisory Services LLC Sells 15,476 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts - Benzinga
Ionis Pharmaceuticals (IONS) Sees Price Target Raised by Piper S - GuruFocus
More Rivalry With Ionis In A Potentially ‘Transformational’ Year For Arrowhead - Citeline News & Insights
Ionis Pharmaceuticals stock hits 52-week high at 86.31 USD By Investing.com - Investing.com South Africa
Ionis Regulatory Wins Highlight Growing Rare Disease Revenue Potential - Sahm
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 1-Year HighWhat's Next? - MarketBeat
Ionis Pharmaceuticals stock hits 52-week high at 86.31 USD - Investing.com
Dawnzera Approval And Pipeline Wins Could Be A Game Changer For Ionis Pharmaceuticals (IONS) - Yahoo Finance
C WorldWide Group Holding A S Sells 24,000 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Insider Sell: C Bennett Sells 85,089 Shares of Ionis Pharmaceuti - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $7,056,430.77 in Stock - MarketBeat
New York State Common Retirement Fund Sells 8,026,750 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Understanding the Setup: (IONS) and Scalable Risk - Stock Traders Daily
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Promising 9.68% Upside in the Biotech Arena - DirectorsTalk Interviews
Insider Sell: Eugene Schneider Sells Shares of Ionis Pharmaceuti - GuruFocus
Ionis Pharma EVP Baroldi sells $439k in shares By Investing.com - Investing.com Nigeria
Ionis Pharma EVP Birchler sells $513,047 in IONS stock By Investing.com - Investing.com Canada
Ionis pharma EVP Swayze sells $512k in IONS stock By Investing.com - Investing.com Canada
Ionis Pharma CFO Hougen sells $581k in shares By Investing.com - Investing.com Canada
Ionis Pharma EVP Baroldi sells $439k in shares - Investing.com
Eric Swayze Sells 6,179 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 5,885 Shares of Stock - MarketBeat
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) CEO Sells 62,970 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Elizabeth Hougen Sells 6,988 Shares - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Brian Birchler Sells 6,179 Shares - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eugene Schneider Sells 6,179 Shares - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 6,179 Shares - MarketBeat
Ionis Pharma EVP O’Neil sells $516k in shares By Investing.com - Investing.com Canada
Ionis Pharma CEO Monia sells $5.2 million in shares By Investing.com - Investing.com Canada
Ionis Pharma EVP Schneider sells $515k in shares By Investing.com - Investing.com Canada
Profit Recap: Can Ionis Pharmaceuticals Inc be recession proofQuarterly Market Summary & Accurate Entry/Exit Alerts - baoquankhu1.vn
Barclays’ Supportive View on Ionis’s RNA Pipeline and Partnerships Might Change The Case For Investing In Ionis Pharmaceuticals (IONS) - Sahm
Privium Fund Management B.V. Sells 18,700 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Lisanti Capital Growth LLC Acquires Shares of 92,124 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis announces proposed convertible offering to refinance 2026 convertible notes - MSN
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Great Lakes Advisors LLC - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Earns Overweight Rating from Analysts at Barclays - MarketBeat
Ionis and Otsuka score EU nod for DAWNZERA, offering new hope for rare HAE patients - Indian Pharma Post
Is Ionis Pharmaceuticals Inc a top pick in the sectorQuarterly Earnings Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 12.94% Potential Upside Amidst Robust Pipeline - DirectorsTalk Interviews
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ionis Pharmaceuticals Inc Azioni (IONS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Monia Brett P | Chief Executive Officer |
Feb 06 '26 |
Sale |
85.79 |
29,430 |
2,524,820 |
254,497 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):